InvestWiser

Egetis Therapeutics AB (publ)

EGTXNasdaq StockholmHealthcareMarket value 5.2 bn SEK
11.14SEK +0.2%
last day · Price as of 18 November 2026

The answer first

Does Egetis Therapeutics beat the market?

Yes, Egetis Therapeutics has beaten the market over the last year.

Egetis Therapeutics+100.4%Stockholm (OMXSGI)+17.6%
  • The ranking · Quality, value and trend combined

    Better than 43% of Nordic stocks

    • Quality45
    • Value2
    • Trend99

    No. 77 of 195 in healthcare

Max for seven days

Follow Egetis Therapeutics with Aurora

Aurora lets you know at the next report. No card.

Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.

Follow your thesis

Follow your thesis on Egetis Therapeutics

From today, at a price of 11.14 SEK. Write why you follow Egetis Therapeutics, and choose what Aurora should tell you about.

What should Aurora follow?

Free, no card. The mission is ready when your account is.

Aurora tells you that something happened. What you do is your choice.

Ask Aurora about Egetis Therapeutics

Your first answer is free, no account needed.

Do you own Egetis Therapeutics, or are you thinking about it?

See it next to the rest of your portfolio, or build your first one with Egetis Therapeutics and a few more. Free, no card.

Past year against the exchange and Super Stock
Egetis Therapeutics+89.8%Stockholm (OMXSGI)+17.6%Super Stock+44.6%
17 November 202518 November 2026
All start at 0 % a year ago, with dividends. Super Stock is our model portfolio: the 20 highest-ranked Nordic stocks on quality, value and trend.

In short

  • Egetis Therapeutics has risen 100.4% over the past year, including dividends.
  • Overall, Egetis Therapeutics ranks better than 43% of Nordic stocks on quality, value and trend.
  • The largest fall over the past three years was 67.0%. The price is 79.0% below its peak now.

What do analysts think of Egetis Therapeutics?

Quality, value and trend

Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.

43

Quality, value and trend together. Better than 43% of Nordic stocks.

No. 77 of 195 in healthcare

Quality45
The company · Fundamentals: the accounts

Medium An average company: the accounts are neither especially strong nor weak.

No. 138 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50

  • Debt to equityBorrowings divided by equity0.25
  • Asset turnoverSales divided by everything the company owns0.11
  • Return on equityProfit divided by equity−138.3%
  • Cash conversionOperating cash flow divided by profit–

The ranking is built on equity ratio, ROA and how steadily profit grows.

Value2
The price · Valuation: the multiples

Low High price: buyers pay a lot today, often because they expect growth.

No. 181 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50

  • P/BPrice divided by equity15.4
  • P/SPrice divided by sales74.7
  • P/EPrice divided by earningsnegative earnings
  • P/CFPrice divided by operating cash flownegative earnings

The ranking is built on P/E, P/B and P/S.

Trend99
The share price · Technical: the price trend

High Tailwind in the share price: it has risen more than most over the last year.

No. 4 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50

  • 3 months+52.0%
  • 6 months+76.0%
  • 9 months+136.5%
  • 12 months+100.4%

The ranking is built on 3, 6 and 12–1 months.

Return and risk

1 month
+21.5%
3 years, per year
+29.7%
5 years, per year
+14.6%
10 years, per year
−4.3%
Largest fall, 3 years
−67.0%
From a peak to the bottom
From the peak now
−79.0%
How far the price is from the peak
Volatility, 1 year
57.2%
How much the price swings over a year
Beta, 1 year
0.41
How much the price moves when the market moves

Return with dividends reinvested.

The funds that own Egetis Therapeutics

10 funds we follow own Egetis Therapeutics. The share is how much of the fund the stock makes up.

  • Norway1
  • Sweden9

From the funds' latest known holdings.

About Egetis Therapeutics

Egetis Therapeutics AB (publ) is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 61 employees.

Egetis Therapeutics AB (publ), a pharmaceutical company, engages in the development and commercialization of orphan drugs in Sweden and internationally. It develops Aladote, which is in Phase IIb/III clinical trial for the treatment of paracetamol/acetaminophen overdosing and for the prevention of acute liver failure in paracetamol poisoning; and Emcitate, which is in Phase IIb clinical trial for the treatment of monocarboxylate transporter 8 deficiency. The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Therapeutics AB (publ) in December 2020. Egetis Therapeutics AB (publ) was incorporated in 2006 and is headquartered in Stockholm, Sweden.

See the full analysis of Egetis Therapeutics.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

Free forever · No card

Other healthcare stocks on Nasdaq Stockholm

Explore the stock market